S-1: Heart Test Laboratories Files for Resale of Up to 34.7 Million Shares of Common Stock

Heart Test Laboratories is registering the resale of up to 34,684,859 shares of its common stock by selling stockholders, including shares issued to Mount Sinai, Lincoln Park Capital, John Q. Adams, and Matthews Southwest Holdings.

Summary

• Heart Test Laboratories has filed a registration statement for the resale of up to 34,684,859 shares of its common stock.
• The shares are being offered by selling stockholders, including Icahn School of Medicine at Mount Sinai, Lincoln Park Capital Fund, John Q. Adams, and Matthews Southwest Holdings, Inc.
• The shares include those issued under securities purchase agreements, note conversion agreements, and pre-funded warrants.
• The company will not receive any proceeds from the sale of shares by the selling stockholders, except from any cash exercise of warrants.
• However, the company will receive proceeds from the sale of shares directly to Lincoln Park Capital under a purchase agreement.
• The last reported sale price of Heart Test Laboratories' common stock on February 28, 2024, was $0.1164 per share.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document is largely factual, outlining the details of the share resale and related agreements. However, the company's financial situation and need to regain Nasdaq compliance introduce a slightly negative tone.

Positives

• The company has secured license agreements with Mount Sinai for AI-ECG algorithms, potentially enhancing its product offerings.
• The company is aiming for FDA clearance of its MyoVista device, which could open up the U.S. market.
• The company has a purchase agreement with Lincoln Park Capital for up to $15 million, providing a potential source of funding.
• The company has been granted an additional 180-day extension to regain compliance with the Minimum Bid Price Requirement.

Negatives

• The company will not receive proceeds from the resale of shares by the selling stockholders, except from potential cash warrant exercises.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has a history of recurring losses and negative cash flows.
• The company needs to regain compliance with the Nasdaq's minimum bid price requirement.

Risks

• The sale or issuance of common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.
• The company may not have access to the full amount available under the Lincoln Park Purchase Agreement.
• The company will need additional capital beyond the capital raised from the sale of the Lincoln Park Shares to Lincoln Park, and the sale of additional shares of our Common Stock, equity and/or debt securities could result in additional dilution to our shareholders.
• Interruptions in computing and data management cloud systems could impair the delivery of our cardiac monitoring services.
• Our proprietary data analytics engine may not operate properly, which could damage our reputation, give rise to claims against us or divert application of our resources from other purposes, any of which could harm our business and operating results.

Future Outlook

The company aims for FDA clearance of its MyoVista device in calendar year 2024 and intends to commercialize licensed AI-ECG algorithms.

Industry Context

The company operates in the medical device industry, which is characterized by rapid technological advancements and intense competition. The company is focused on applying innovative AI-based technology to ECG to improve its clinical usefulness.

Related Party Transactions

• The document mentions transactions with John Q. Adams and Matthews Southwest Holdings, Inc., who may be considered related parties due to their previous or current relationships with the company.

Stakeholder Impact

• The resale of shares may cause dilution to existing shareholders.
• The success of the company's products and technology will impact patients, physicians, health systems, and third-party payors.

Next Steps

• The selling stockholders may offer and sell all or a portion of their shares from time to time.
• The company intends to work quickly to obtain regulatory approval on a number of key algorithms.
• The company intends to make the algorithms available worldwide on an ECG hardware agnostic basis through the use of Health Insurance Portability and Accountability Act (HIPAA) and European General Data Protection Regulation (GDPR) compliant cybersecure cloud-based environment.

Key Dates

Keywords

common stock, resale, Heart Test Laboratories, Lincoln Park Capital, Mount Sinai, warrants, AI-ECG, MyoVista, FDA clearance, securities